The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations

The liver acts as a hub for metabolic reactions to keep a homeostatic balance during development and growth. The process of liver cancer development, although poorly understood, is related to different etiologic factors like toxins, alcohol, or viral infection. At the molecular level, liver cancer is characterized by a disruption of cell cycle regulation through many molecular mechanisms. In this review, we focus on the mechanisms underlying the lack of regulation of the cell cycle during liver cancer, focusing mainly on hepatocellular carcinoma (HCC). We also provide a brief summary of novel therapies connected to cell cycle regulation.

[1]  M. Seto,et al.  Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma , 1999, Journal of Gastroenterology.

[2]  Junping Zhang,et al.  MicroRNA-520b Inhibits Growth of Hepatoma Cells by Targeting MEKK2 and Cyclin D1 , 2012, PloS one.

[3]  M. Romeih,et al.  Wnt signaling in hepatocellular carcinoma: Analysis of mutation and expression of beta‐catenin, T‐cell factor‐4 and glycogen synthase kinase 3‐beta genes , 2003, Journal of gastroenterology and hepatology.

[4]  C. J. Chen,et al.  Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.

[5]  Y. I. Lee,et al.  Hepatitis B virus-X protein upregulates the expression of p21wafl/cipl and prolongs G1→S transition via a p53-independent pathway in human hepatoma cells , 2000, Oncogene.

[6]  J. LaBaer,et al.  New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.

[7]  R. Eils,et al.  Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis , 2007, Hepatology.

[8]  M. Roncalli,et al.  Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. , 1995, Gastroenterology.

[9]  T. Sakurai,et al.  Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1. , 2013, Biochemical and biophysical research communications.

[10]  E. Yu,et al.  p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. , 2003, Cancer letters.

[11]  G. Fattovich,et al.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.

[12]  Amar Deep Sharma,et al.  Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. , 2008, Cancer cell.

[13]  Yeup Yoon,et al.  Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-κB-dependent expression of interleukin-8. , 2011, Cancer research.

[14]  J Wade Harper,et al.  Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. , 2007, Molecular cell.

[15]  Y. Choi,et al.  Signaling through cyclin D-dependent kinases , 2014, Oncogene.

[16]  J. Inazawa,et al.  Activation of B‐Myb by E2F1 in hepatocellular carcinoma , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  W. Lau,et al.  High frequency of p16INK4A gene alterations in hepatocellular carcinoma , 1999, Oncogene.

[18]  Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. , 2006, Journal of hepatology.

[19]  S. Osada,et al.  Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. , 2005, Journal of the American College of Surgeons.

[20]  Rolf Gebhardt,et al.  Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma , 2008, Molecular Cancer.

[21]  James M. Roberts,et al.  Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. , 2003, Molecular cell.

[22]  Ji-Yeon Kim,et al.  Up-regulation of Cyclin D1 by HBx Is Mediated by NF-κB2/BCL3 Complex through κB Site of Cyclin D1 Promoter* , 2006, Journal of Biological Chemistry.

[23]  J. Zucman‐Rossi,et al.  Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping , 2002, Oncogene.

[24]  C. Sherr,et al.  Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase , 1994, Molecular and cellular biology.

[25]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[26]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[27]  H Nagahara,et al.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Eriksson,et al.  Induced drug resistance inhibits selection of initiated cells and cancer development. , 1997, Carcinogenesis.

[29]  Chia-Hsin Chan,et al.  Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression , 2010, TheScientificWorldJournal.

[30]  M. Takamura,et al.  Clinical significance of cell cycle inhibitors in hepatocellular carcinoma , 2013, Medical Molecular Morphology.

[31]  Ji-Yeon Kim,et al.  Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. , 2006, The Journal of biological chemistry.

[32]  M. Makuuchi,et al.  p16INK4A Hypermethylation Is Associated with Hepatitis Virus Infection, Age, and Gender in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[33]  S. Thorgeirsson,et al.  RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. , 2007, Gastroenterology.

[34]  S. Fan,et al.  Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma , 2007, Cancer biology & therapy.

[35]  M. Hayat 1 Liver carcinoma , 2005 .

[36]  J. Albrecht,et al.  Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver , 1998, Oncogene.

[37]  Jing Fu,et al.  Oncoprotein p28GANK binds to RelA and retains NF-κB in the cytoplasm through nuclear export , 2007, Cell Research.

[38]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[39]  Hong-guang Zhu,et al.  Association of p16INK4A hypermethylation with hepatitis B virus X protein expression in the early stage of HBV‐associated hepatocarcinogenesis , 2007, Pathology international.

[40]  Jean S. Campbell,et al.  Liver regeneration. , 2012, Journal of hepatology.

[41]  Hong-Yang Wang,et al.  Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[42]  C. Bréchot,et al.  Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma , 1990, Nature.

[43]  S. Thorgeirsson,et al.  Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway , 2011, The Journal of experimental medicine.

[44]  C. Maki,et al.  Cdk2-dependent Inhibition of p21 Stability via a C-terminal Cyclin-binding Motif* , 2005, Journal of Biological Chemistry.

[45]  K. Meyer,et al.  Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. , 1998, Gene.

[46]  H. Hsu,et al.  Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. , 1998, Journal of hepatology.

[47]  M. Chen,et al.  Activation of p53 tumor suppressor by hepatitis C virus core protein. , 1999, Virology.

[48]  Y. Shiratori,et al.  Hepatitis C Virus Core Protein Enhances p53 Function through Augmentation of DNA Binding Affinity and Transcriptional Ability* , 2000, The Journal of Biological Chemistry.

[49]  J. Zucman‐Rossi,et al.  Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma , 2001, Oncogene.

[50]  E. Wagner,et al.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. , 2008, The Journal of clinical investigation.

[51]  S. Seki,et al.  Expression of the retinoblastoma gene product in human hepatocellular carcinoma. , 1995, Human pathology.

[52]  S. Thorgeirsson,et al.  Exploring genomic profiles of hepatocellular carcinoma , 2011, Molecular carcinogenesis.

[53]  M. Ozturk,et al.  Lithium‐mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells , 2005, International journal of cancer.

[54]  H. Asakura,et al.  Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  Fangping Xu,et al.  Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. , 2006, American journal of clinical pathology.

[56]  A. Wilkinson,et al.  Gankyrin: a new oncoprotein and regulator of pRb and p53. , 2006, Trends in cell biology.

[57]  M. Monden,et al.  Expression and prognostic roles of the G1‐S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence , 1999, Hepatology.

[58]  H. Wang,et al.  TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1–Forkhead box M1 regulation loop , 2008, Hepatology.

[59]  M. Barton,et al.  Cascades of transcription regulation during liver regeneration. , 2011, The international journal of biochemistry & cell biology.

[60]  T. Chibazakura,et al.  Cyclin A overexpression induces chromosomal double-strand breaks in mammalian cells , 2009, Cell cycle.

[61]  N. Hayashi,et al.  Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.

[62]  G. Michalopoulos Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. , 2010, The American journal of pathology.

[63]  R. Assoian,et al.  Transcriptional regulation of the cyclin D1 gene at a glance , 2008, Journal of Cell Science.

[64]  I. Rusyn,et al.  Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[65]  Hong-Yang Wang,et al.  The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling , 2011, Cell Research.

[66]  M. Manns,et al.  The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice , 2013, Hepatology.

[67]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[68]  Lu-Yu Hwang,et al.  Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.

[69]  K. McGlynn,et al.  Epidemiology and natural history of hepatocellular carcinoma. , 2005, Best practice & research. Clinical gastroenterology.

[70]  Jessica Zucman-Rossi,et al.  Molecular classification of hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[71]  G. Michalopoulos,et al.  Beta-catenin is temporally regulated during normal liver development. , 2004, Gastroenterology.

[72]  K. Engeland,et al.  Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma , 2000, International journal of cancer.

[73]  M. Matsuda,et al.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis , 2003, International journal of cancer.

[74]  D. Gilot,et al.  Regulation and role of p21 and p27 cyclin-dependent kinase inhibitors during hepatocyte differentiation and growth. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[75]  M. Mudryj,et al.  Hepatitis C virus core protein expression leads to biphasic regulation of the p21 cdk inhibitor and modulation of hepatocyte cell cycle. , 2003, Virology.

[76]  P. Kaldis,et al.  Established and novel Cdk/cyclin complexes regulating the cell cycle and development. , 2011, Results and problems in cell differentiation.

[77]  J. Isola,et al.  Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. , 2001, Cancer research.

[78]  K. Nakayama,et al.  Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. , 2013, Cancer cell.

[79]  Wen Li,et al.  Clinical significance of miR-221 and its inverse correlation with p27Kip1 in hepatocellular carcinoma , 2011, Molecular Biology Reports.

[80]  H. Müller-Hermelink,et al.  Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. , 1997, Blood.

[81]  Chun Cheng,et al.  Mutant p27(Kip1) and its potential effect as hepatocellular gene therapy. , 2008, Archives of medical research.

[82]  F. Bosman,et al.  Germ‐line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma , 1997, Hepatology.

[83]  J. Marrero,et al.  Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort , 2005, Hepatology.

[84]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[85]  Qifu Liu,et al.  Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas. , 1998, World journal of gastroenterology.

[86]  M. Loda,et al.  Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  P. Fisher,et al.  Hepatitis B virus X protein increases expression of p21Cip‐1/WAF1/MDA6 and p27Kip‐1 in primary mouse hepatocytes, leading to reduced cell cycle progression , 2001 .

[88]  K. Ogawa,et al.  Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis , 2006, Molecular carcinogenesis.

[89]  Jian-Rong Yang,et al.  MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.

[90]  K. Jang,et al.  Cooperative repression of cyclin‐dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein , 2002, FEBS letters.

[91]  H. Willenbring,et al.  A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice , 2008, Nature Protocols.

[92]  S. M. Rubin Deciphering the retinoblastoma protein phosphorylation code. , 2013, Trends in biochemical sciences.

[93]  G. Hannon,et al.  p21-containing cyclin kinases exist in both active and inactive states. , 1994, Genes & development.

[94]  S. Imbeaud,et al.  Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification , 2013, Hepatology.

[95]  M. Makuuchi,et al.  Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. , 2000, Cancer letters.

[96]  S. Hirohashi,et al.  Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.

[97]  O. Bachs,et al.  Activation of Cdk4 and Cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin‐Cdk complexes , 1999, Hepatology.

[98]  S. Thorgeirsson,et al.  Comparative and integrative functional genomics of HCC , 2006, Oncogene.

[99]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[100]  H. Kwun,et al.  Transcriptional repression of p21(waf1) promoter by hepatitis B virus X protein via a p53-independent pathway. , 2001, Gene.

[101]  J. Kao,et al.  Prevention of hepatocellular carcinoma in the Asia–Pacific region: Consensus statements , 2010, Journal of gastroenterology and hepatology.

[102]  I. Ng,et al.  Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. , 2001, Human pathology.

[103]  Qi Chen,et al.  Hepatitis B virus X protein promotes hypermethylation of p16(INK4A) promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis. , 2010, Experimental and molecular pathology.

[104]  L. Gravitz Liver cancer , 2014, Nature.

[105]  Qi Chen,et al.  Hepatitis B virus X protein induces hypermethylation of p16INK4A promoter via DNA methyltransferases in the early stage of HBV‐associated hepatocarcinogenesis , 2010, Journal of viral hepatitis.

[106]  C-Y Chen,et al.  Retinoblastoma protein modulates gankyrin–MDM2 in regulation of p53 stability and chemosensitivity in cancer cells , 2008, Oncogene.

[107]  C. Guguen-Guillouzo,et al.  Growth factor dependence of progression through G1 and S phases of adult rat hepatocytes in vitro. Evidence of a mitogen restriction point in mid-late G1. , 1996, The Journal of biological chemistry.

[108]  P. Gruppuso,et al.  D-type cyclins and G1 progression during liver development in the rat. , 2005, Biochemical and biophysical research communications.

[109]  Sheng-Nan Lu,et al.  P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[110]  Tomoko Masuda,et al.  The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. , 2005, Cancer cell.

[111]  C. Croce,et al.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.

[112]  P. Schirmacher,et al.  Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.

[113]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[114]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[115]  M. Joo,et al.  Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. , 2003, Journal of Korean medical science.

[116]  W. Baek,et al.  5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. , 2000, Cancer letters.

[117]  Robert L. Sutherland,et al.  Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.

[118]  E. Kipreos,et al.  Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. , 2012, Trends in cell biology.

[119]  C. Verslype,et al.  Molecular classification of hepatocellular carcinoma anno 2011. , 2011, European journal of cancer.

[120]  N. Nishida,et al.  Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma: A Systematic Review , 2011, Current genomics.

[121]  M. Chung,et al.  CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. , 2010, Anticancer research.

[122]  I. Ng,et al.  High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. , 2004, Human pathology.

[123]  S. Hirohashi,et al.  Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. , 1994, Cancer research.

[124]  Arun J. Sanyal,et al.  Zakim and Boyer's Hepatology: A Textbook of Liver Disease , 2016 .

[125]  M. Makuuchi,et al.  Over‐expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma , 1999, International journal of cancer.

[126]  C. Guguen-Guillouzo,et al.  Growth Factor Dependence of Progression through G and S Phases of Adult Rat Hepatocytes in Vitro , 1996, The Journal of Biological Chemistry.

[127]  Maylis Delugin,et al.  FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients , 2007, Cell Division.

[128]  E. Tabor Hepatocellular carcinoma: global epidemiology. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[129]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[130]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[131]  Xuegong Zhang,et al.  An overview of hepatocellular carcinoma study by omics-based methods. , 2009, Acta biochimica et biophysica Sinica.

[132]  Shiaw-Yih Lin,et al.  Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. , 2003, Cancer research.

[133]  J. Albrecht,et al.  Regulation of cyclin‐dependent kinase inhibitor p21WAF1/Cip1/Sdi1 gene expression in hepatic regeneration , 1997, Hepatology.

[134]  K. Migita,et al.  Liver architecture, cell function, and disease , 2009, Seminars in Immunopathology.

[135]  Nathan H. Lents,et al.  Cyclin A-CDK activity during G1 phase impairs MCM chromatin loading and inhibits DNA synthesis in mammalian cells , 2008, Cell cycle.

[136]  M. Toyota,et al.  Detection of hypermethylation of thep16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus , 2001, Gut.

[137]  D. Calvisi,et al.  SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. , 2009, Gastroenterology.

[138]  C. la Vecchia,et al.  Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. , 2009, Cancer letters.

[139]  D. Stolz,et al.  Changes in WNT/beta-catenin pathway during regulated growth in rat liver regeneration. , 2001, Hepatology.

[140]  Tae J. Lee,et al.  A bistable Rb–E2F switch underlies the restriction point , 2008, Nature Cell Biology.

[141]  C. Bréchot,et al.  Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. , 1995, Journal of hepatology.

[142]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[143]  C. Dai,et al.  Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine‐45 mutant β‐catenin , 2010, Hepatology.

[144]  H. M. Reis,et al.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.

[145]  Li-Huei Tsai,et al.  Cyclin-dependent kinases: a family portrait , 2009, Nature Cell Biology.

[146]  M. Ebara [Hepatocellular carcinoma (HCC)]. , 1995, Ryōikibetsu shōkōgun shirīzu.

[147]  Bruce Stillman,et al.  Deregulation of cyclin E in human cells interferes with prereplication complex assembly , 2004, The Journal of cell biology.

[148]  N. Nishida,et al.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. , 1994, Cancer research.

[149]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[150]  J. Diehl Cycling to Cancer with Cyclin D1 , 2002, Cancer biology & therapy.

[151]  A. Matsuura,et al.  Loss of p27(Kip1) accelerates DNA replication after partial hepatectomy in mice. , 2003, The Journal of surgical research.

[152]  Y. Dang,et al.  Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro , 2013, BMC Cancer.

[153]  Shih-Ming Huang,et al.  Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells , 2013, PloS one.

[154]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[155]  Martin Wasser,et al.  Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration , 2012, Proceedings of the National Academy of Sciences.

[156]  P. Fortina,et al.  RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. , 2011, Gastroenterology.

[157]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[158]  M. Yano,et al.  Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up‐regulation of cytoplasmic p21 expression , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[159]  F. Izzo,et al.  BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy , 2012, Cell Death and Disease.

[160]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[161]  K. Rao,et al.  Overexpression of cyclin D1 is associated with elevated levels of MAP kinases, Akt and Pak1 during diethylnitrosamine‐induced progressive liver carcinogenesis , 2007, Cell biology international.

[162]  Xin Zheng,et al.  Recombinant Human Adenovirus-p53 Injection Induced Apoptosis in Hepatocellular Carcinoma Cell Lines Mediated by p53-Fbxw7 Pathway, Which Controls c-Myc and Cyclin E , 2013, PloS one.

[163]  M. Yuen,et al.  Expression of c‐Myc, c‐Fos, and c‐Jun in hepatocellular carcinoma , 2001, Cancer.

[164]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[165]  Liang Zhu,et al.  Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation. , 2007, Carcinogenesis.

[166]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[167]  Katsuhiko Itoh,et al.  Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas , 2000, Nature Medicine.

[168]  J. Fassett,et al.  Differential regulation of cyclins D1 and D3 in hepatocyte proliferation , 2002, Hepatology.

[169]  F. Dick Structure-function analysis of the retinoblastoma tumor suppressor protein – is the whole a sum of its parts? , 2007, Cell Division.

[170]  Allan Balmain,et al.  Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene , 2004, Nature.

[171]  J. Kononen,et al.  Cyclin E overexpression and amplification in human tumours , 2003, The Journal of pathology.

[172]  Zhou Zhu,et al.  Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma , 2013, Hepatology.

[173]  G. Babcock,et al.  Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. , 2005, Cancer research.

[174]  Xin Chen,et al.  Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. , 2009, Cancer research.

[175]  Derek Y. Chiang,et al.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. , 2009, Journal of hepatology.

[176]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[177]  Q. Zou,et al.  Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. , 2005, World journal of gastroenterology.

[178]  A. Bahnassy,et al.  The role of cyclins and cyclin dependent kinases in development and progression of hepatitis C virus-genotype 4-associated hepatitis and hepatocellular carcinoma. , 2011, Experimental and molecular pathology.

[179]  G. Cao,et al.  p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3‐kinase/AKT/hypoxia‐inducible factor‐1α pathways , 2011, Hepatology.

[180]  N. Tabibian Hepatocellular carcinoma in the United States. , 1988, American family physician.

[181]  I. Ng,et al.  Expression of p27KIP1 and p21WAF1/CIP1 in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis , 2001 .

[182]  Robert A. Weinberg,et al.  Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.

[183]  S. Reed,et al.  FBXW7/hCDC4 is a general tumor suppressor in human cancer. , 2007, Cancer research.

[184]  G. Farrell,et al.  Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis , 2013, Journal of gastroenterology and hepatology.

[185]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[186]  S. Thorgeirsson,et al.  Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. , 2006, Gastroenterology.

[187]  J. Jang,et al.  Cyclin D1 overexpression in hepatocellular carcinoma. , 2001, Liver.

[188]  E. Knudsen,et al.  RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1 , 2009, Oncogene.

[189]  T. Kodama,et al.  Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. , 2002, Biochemical and biophysical research communications.

[190]  K. Nakayama,et al.  Ubiquitin ligases: cell-cycle control and cancer , 2006, Nature Reviews Cancer.

[191]  T. Hunter,et al.  Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors , 2010, Cell cycle.

[192]  H. Yang,et al.  The repressive activity of hepatitis C virus core protein on the transcription of p21(waf1) is regulated by protein kinase A-mediated phosphorylation. , 2001, Virus research.

[193]  Karl A. Merrick,et al.  Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. , 2008, Molecular cell.

[194]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[195]  M. Ozturk,et al.  Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells , 2001, Oncogene.

[196]  J. Oh,et al.  Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. , 2001, Cancer letters.

[197]  C. Taylor Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas , 2006 .

[198]  P. Dent,et al.  Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. , 2001, Hepatology.

[199]  W. Lingle,et al.  Short Term Cyclin D1 Overexpression Induces Centrosome Amplification, Mitotic Spindle Abnormalities, and Aneuploidy* , 2005, Journal of Biological Chemistry.

[200]  S. Hirohashi,et al.  Reduced p27Kip1 expression in hepatocellular carcinomas. , 1998, Cancer letters.

[201]  Y. N. Park,et al.  Histopathological classification of hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[202]  Y. Shyr,et al.  Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. , 2001, Cancer research.

[203]  Y. Gong,et al.  Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E. , 2012, Gastroenterology.

[204]  X. Graña,et al.  Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. , 2010, Gastroenterology.

[205]  S. Rajalakshmi,et al.  Development of resistance during the early stages of experimental liver carcinogenesis. , 1999, Carcinogenesis.

[206]  J. Albrecht,et al.  Cyclin D1 promotes mitogen-independent cell cycle progression in hepatocytes. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[207]  W. Hahn,et al.  Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. , 2012, Blood.

[208]  Chun Cheng,et al.  Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro , 2011, Medical oncology.

[209]  F. Ponchel,et al.  P53 but not p16INK4a induces growth arrest in retinoblastoma-deficient hepatocellular carcinoma cells. , 2000, Journal of hepatology.

[210]  T. Chibazakura Cyclin Proteolysis and CDK Inhibitors: Two Redundant Pathways to Maintain Genome Stability in Mammalian Cells , 2004, Cell cycle.

[211]  Yuqiong Liang,et al.  Hepatitis C Virus Induces E6AP-Dependent Degradation of the Retinoblastoma Protein , 2007, PLoS pathogens.

[212]  L. Hengst,et al.  CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point , 2013, PLoS genetics.

[213]  Yingying Wang,et al.  Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). , 2013, Human pathology.

[214]  Y. Tan,et al.  Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. , 2001, World journal of gastroenterology.

[215]  J. Yun,et al.  MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells , 2009, Hepatology.

[216]  Chien-Ru Liu,et al.  Targeting c-Myc as a novel approach for hepatocellular carcinoma. , 2010, World journal of hepatology.

[217]  B. Leggett,et al.  Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population , 1997, Hepatology.

[218]  S. Hirohashi,et al.  Reduced p21WAF1/CIP1 expression and p53 mutation in hepatocellular carcinomas , 1997, Hepatology.

[219]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[220]  H. Vodermaier,et al.  APC/C and SCF: Controlling Each Other and the Cell Cycle , 2004, Current Biology.

[221]  H. El‐Serag,et al.  Chapter 10 – Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis , 2012 .

[222]  D. Stolz,et al.  Changes in WNT/β‐catenin pathway during regulated growth in rat liver regeneration , 2001 .

[223]  M. Kaneko,et al.  Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors. , 1991, Japanese journal of clinical oncology.

[224]  Lincoln D. Stein,et al.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.

[225]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[226]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[227]  O. Bachs,et al.  Differential association of p21Cip1 and p27Kip1 with cyclin E-CDK2 during rat liver regeneration. , 2000, Journal of hepatology.

[228]  B. Clurman,et al.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation , 2008, Nature Reviews Cancer.

[229]  Yuqiong Liang,et al.  Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[230]  F. Dick,et al.  The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle , 2012, Cell Division.

[231]  Miran Kim,et al.  Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.

[232]  P. Tan,et al.  Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. , 2004, International journal of oncology.

[233]  S. Boyault,et al.  Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.

[234]  F. Cerra,et al.  Distinct patterns of cyclin D1 regulation in models of liver regeneration and human liver. , 1995, Biochemical and biophysical research communications.

[235]  Xin Zheng,et al.  Evaluation of Fbxw7 expression and its correlation with the expression of c‐Myc, cyclin E and p53 in human hepatocellular carcinoma , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.